Destination
Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth. [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Windscribe review: Despite the annoyances, it has the right idea

Windscribe is a virtual private network (VPN) with intense "How do you do, fellow kids?" energy. It has servers in 69 countries and an annual plan that costs $69, an obsession with the sex n [...]

Match Score: 111.45

Destination
CyberGhost VPN review: Despite its flaws, the value is hard to beat

CyberGhost is the middle child of the Kape Technologies VPN portfolio, but in quality, it's much closer to ExpressVPN than Private Internet Access. I mainly put it on my best VPN list because it& [...]

Match Score: 104.70

Destination
Mullvad VPN review: Near-total privacy with a few sacrifices

Mullvad, a virtual private network (VPN) named after the Swedish word for "mole," is often recognized as one of the best VPNs for privacy. I put it on my best VPN list for exactly that reaso [...]

Match Score: 94.23

Destination
Private Internet Access VPN review: Both more and less than a budget VPN

I came into this review thinking of Private Internet Access (PIA) as one of the better VPNs. It's in the Kape Technologies portfolio, along with the top-tier ExpressVPN and the generally reliable [...]

Match Score: 92.69

Destination
Norton VPN review: A VPN that fails to meet Norton's standards

One thing I need to make clear right from the start: this is a review of Norton VPN (formerly Norton Secure VPN, and briefly Norton Ultra VPN) as a standalone app, not of the VPN feature in the Norton [...]

Match Score: 79.92

blogspot
Ahrefs vs SEMrush: Which SEO Tool Should You Use?

SEMrush and Ahrefs are among<br /> the most popular tools in the SEO industry. Both companies have been in<br /> business for years and have thousands of customers per month.<br /> & [...]

Match Score: 59.70

qz
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?

BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular portfolio faces mixed developments. [...]

Match Score: 49.55

qz
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?

BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook. [...]

Match Score: 49.55

Destination
Pfizer, drug companies make 'no commitments' to White House about lowering drug prices

Cheaper pharmaceuticals won’t be on shelves any time soon, says the CEO of Pfizer. That’s despite an executive order signed last month declaring a war on drug prices, which at one point President [...]

Match Score: 40.36